Ou: a cadeia que nasceu de uma sentença Since August 4th, ANVISA (Brazilian Health Regulatory Agency) has been receiving requests for Special Authorization from companies interested in cultivating Cannabis sativa in Brazil for medicinal purposes. This date marks the operational start of a new production chain, but news reports still primarily treat the issue as another step in the regulation of cannabis. The most interesting aspect lies elsewhere: the timeline for medicinal c

In the first half of 2026, pharmaceutical and artificial intelligence companies announced fourteen major deals totaling at least US$23.6 billion in potential value, according to a survey by analyst Oliver Sprague Kelly. The prevailing interpretation was that the pharmaceutical industry is betting heavily on radical innovation . I spent a good part of my twenty-five years in the industry in environments where such agreements are discussed and approved, and those who have lived

In recent days, after I wrote about PNIRS, I received the same question from founders, researchers, and investors, phrased in different ways: and the money, where is the money? I heard this from people I've known for years, people who built good science within universities, started companies, won grants, and then saw their projects stall not due to technical failures, but due to a lack of a next step . It is about this next step that I want to write, because it contains the m